该产品为ADHD（注意缺陷多动障碍）智能化行为治疗管理的临床应用提供了创新的解决路径，是推动 公司多模态ADHD行为训练系统实现应用场景落地的关键里程碑。 人民财讯9月5日电，爱朋医疗（300753）9月5日晚间公告，公司控股子公司深圳朋睿脑科学技术有限公 司近日取得广东省药监局颁发的《医疗器械注册证》，产品名称分别为便携式脑电图机和便携式脑电采 集器，型号分别为UMind Pro和UMind SE，是公司"多模态ADHD行为训练系统"的核心组成部分，主要 用于脑电信号的检测、显示、存储和传输。 ...

爱朋医疗公告，控股子公司深圳朋睿脑科学技术有限公司近日取得广东省药品监督管理局颁发的《中华 人民共和国医疗器械注册证》。该注册证涉及的产品包括便携式脑电图机和便携式脑电采集器，注册证 有效期均为5年。便携式脑电图机注册证编号为粤械注准20252071190，便携式脑电采集器注册证编号为 粤械注准20252071188。这两款产品是公司"多模态ADHD行为训练系统"的核心组成部分，有助于推动 公司在脑科学、神经系统疾病诊断、认知训练领域的应用拓展，对未来发展产生积极影响。 ...

Group 1 - The Ministry of Industry and Information Technology, along with several other government bodies, has issued an implementation opinion to promote the innovation and development of the brain-computer interface (BCI) industry, aiming for significant breakthroughs in key technologies by 2027 and the establishment of a competitive industrial ecosystem by 2030 [1] - The opinion outlines a high-quality development goal for the BCI industry, focusing on five areas: strengthening basic hardware and software, creating high-performance products, promoting technology transfer, expanding innovation entities, and enhancing industrial support capabilities [1] - Specific actions include three major projects: core hardware and software strengthening, high-quality complete machine engineering, and application expansion, with 17 detailed measures to build a comprehensive innovation promotion system [1] Group 2 - The opinion encourages the development of non-invasive BCI products that are lightweight, low-power, and wearable, while also promoting integrated BCI products for consumer applications [2] - In the healthcare sector, the focus is on addressing neurodegenerative and mental disorders, enhancing research on pathological and physiological mechanisms, and innovating neuro-regulation technologies to improve diagnosis and treatment levels [2] - Aipeng Medical (300753) is positioned to benefit from new opportunities in the BCI field, aligning its innovative products for ADHD, anesthesia management, and sleep assessment with the non-invasive application path outlined in the opinion [2] Group 3 - Aipeng Medical's new generation ADM series anesthesia depth monitor utilizes non-invasive EEG monitoring technology to provide quantitative references for anesthesiologists, helping to assess patients' consciousness levels during anesthesia [3] - The device has achieved upgrades in algorithm accuracy, EEG spectrum visualization, and stability, making EEG monitoring more continuous, real-time, stable, and accurate [3] - In the field of neuro-rehabilitation, Aipeng Medical's subsidiary focuses on the development of digital therapeutic products for diagnosing neurological diseases, cognitive training, and sleep monitoring [3] Group 4 - Aipeng Medical is implementing BCI technology across multiple brands in sleep management, with a focus on non-drug therapies like the t-VNS device for improving sleep disorders and alleviating anxiety [4] - Collaborations with companies like Shenzhen Yunrui have led to the development of sleep monitoring devices that provide precise quantification and analysis of sleep processes [4] - The company is creating a comprehensive sleep management system that integrates various products to standardize diagnosis and treatment, ensuring data integration and management closure [4] - The implementation opinion provides a top-level design for the foundational research and engineering efforts in BCI technology, opening policy channels for its application in healthcare, sleep medicine, and cognitive rehabilitation [4]

Core Viewpoint - The establishment of the Aipeng Medical Artificial Intelligence and Brain-Computer Interface Research Institute marks a significant step in the integration of brain science and AI, aiming to drive innovation in the medical field through advanced technology [1][3]. Group 1: Research Institute and Expert Involvement - The research institute has appointed a group of experts from prestigious institutions to support Aipeng Medical in technology innovation, product implementation, and industry collaboration [3]. - The chairman of Aipeng Medical emphasized the importance of embracing the opportunities presented by AI and brain-computer interface technologies to explore new possibilities at the intersection of technology and clinical applications [3]. Group 2: Market Growth and Focus Areas - The global brain-computer interface market has grown from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13%, and is projected to reach $7.63 billion by 2029 [5]. - The research institute will focus on three main areas: pain management, anesthesia and sedation, and mental health treatment, aiming to enhance medical service quality and efficiency [5]. Group 3: Clinical Applications and Innovations - Approximately 27% of the global population suffers from sleep disorders, with nearly 300 million affected in China, highlighting the need for innovative solutions in sleep medicine [7]. - Aipeng Medical's new generation ADM anesthesia depth monitor leverages non-invasive EEG technology and AI to provide real-time monitoring and precise staging of sleep, paving the way for intelligent solutions in sleep medicine [7]. - The company is also developing brain-computer interface products for ADHD treatment, utilizing game-based interactive designs to enhance engagement and compliance among children [9]. Group 4: Long-term Technological Innovation - Aipeng Medical has a history of strategic investments in brain-computer interface technologies, including partnerships and product launches since 2019, indicating a systematic approach to this high-barrier field [13]. - The establishment of the research institute aims to bridge the gap between academia and industry, facilitating a collaborative environment for technological advancements [14][16]. - The company plans to leverage the research institute to drive long-term technological innovation and transition from a traditional medical device manufacturer to an AI-driven medical technology platform [16].

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 据悉，2025年3月31日，湖北率先为脑机接口医疗服务定价，明确3个项目收费标准，为未来技术落地服务患者打下基础。 | 项目名称 | 价格(元/次) | | --- | --- | | 侵入式脑机接口 置入费 | 6552 | | 侵入式脑机接口 取出费 | 3139 | | 非侵入式脑机接口 适配費 | ે રેણ | # 意义分析 2025年3月12日，国家医保局发布 《神经系统类医疗服务价格项目立项指南》 ，其中专门为脑机接口新技术单独立项，设立了侵入式脑机接口置入费、取出费，非侵入式脑机接口适配费等价格项目。这意味着，一旦脑机接口技术成 熟，快速进入临床应用的收费路径已经铺好。 湖北省医保局于2025年3月31日发布全国首个脑机接口医疗服务价格，这一举措具有多方面的重要意义。 对医疗行业的意义： 此前脑机接口技术因收费模糊难以大规模临床应用，定价之后 3月中旬，国家医保局发布《神经系统类医疗服务价格项目立项指南》，其中专门为脑机接口新技术价格单独 ...